Top Markets
Coin of the day
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
株式のランク #29675
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
株価
$0.20877985
時価総額
$20.11M
変化(1日)
-3.03%
変化(1年)
-66.13%
JP
取引 Modalis Therapeutics Corporation (4883)

カテゴリー

Modalis Therapeutics Corporation(4883)の収益
Aug 2026 時点の収益 TTM: 0
Modalis Therapeutics Corporation の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Modalis Therapeutics Corporation の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.70B -
AU
- -
CH